Greenwich, CT, United States of America

Eduardo Forleo Neto


Average Co-Inventor Count = 7.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2024-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Eduardo Forleo Neto

Introduction

Eduardo Forleo Neto is a notable inventor based in Greenwich, CT (US). He has made significant contributions to the field of medicine, particularly in the treatment of rare diseases and viral infections. With a total of 2 patents, his work has the potential to impact many lives.

Latest Patents

Eduardo's latest patents include groundbreaking methods for treating fibrodysplasia ossificans progressiva (FOP) and SARS-CoV-2 infections. The first patent focuses on the treatment of FOP by administering an anti-activin A antibody. This method involves providing a therapeutically effective amount of an activin A antagonist to individuals suffering from this rare condition. The second patent addresses the prevention and treatment of SARS-CoV-2 infections and COVID-19. It features the administration of antigen-binding molecules, such as antibodies, that target the spike protein of the virus.

Career Highlights

Eduardo Forleo Neto is currently associated with Regeneron Pharmaceuticals, Inc., a leading biotechnology company. His work at Regeneron has allowed him to collaborate with other talented professionals in the field, contributing to innovative solutions for pressing health issues.

Collaborations

Some of Eduardo's notable coworkers include Gary Herman and Samit Ganguly. Their combined expertise fosters a collaborative environment that enhances the development of new therapeutic methods.

Conclusion

Eduardo Forleo Neto's contributions to medical innovation, particularly in the treatment of FOP and COVID-19, highlight his dedication to improving patient outcomes. His work at Regeneron Pharmaceuticals, Inc. continues to pave the way for future advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…